CoChat

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer

Open access
Fernandez, Harvey R., Gadre, Shreyas M., Tan, Mingjun, Graham, Garrett T., Mosaoa, Rami, Ongkeko, Martin S., Kim, Kyu Ah, Riggins, Rebecca B., Parasido, Erika, Petrini, Iacopo, Pacini, Simone, Cheema, Amrita, Varghese, Rency, Ressom, Habtom W, Zhang, Yuwen, Albanese, Christopher, Üren, Aykut, Paige, Mikell, Giaccone, Giuseppe, Avantaggiati, Maria Laura · 2018 · Cell Death & Differentiation
Cited by 139

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Therapy resistance represents a clinical challenge for advanced non-small cell lung cancer (NSCLC), which still remains an incurable disease. There is growing evidence that cancer-initiating or cancer stem cells (CSCs) provide a reservoir of slow-growing dormant populations of cells with tumor-initiating and unlimited self-renewal ability that are left behind by conventional therapies reigniting post-therapy relapse and metastatic dissemination. The metabolic pathways required for the expansion of CSCs are incompletely defined, but their understanding will likely open new therapeutic opportunities. We show here that lung CSCs rely upon oxidative phosphorylation for energy production and survival through the activity of the mitochondrial citrate transporter, SLC25A1. We demonstrate that SLC25A1 plays a key role in maintaining the mitochondrial pool of citrate and redox balance in CSCs, whereas its inhibition leads to reactive oxygen species build-up thereby inhibiting the self-renewal capability of CSCs. Moreover, in different patient-derived tumors, resistance to cisplatin or to epidermal growth factor receptor (EGFR) inhibitor treatment is acquired through SLC25A1-mediated implementation of mitochondrial activity and induction of a stemness phenotype. Hence, a newly identified specific SLC25A1 inhibitor is synthetic lethal with cisplatin or with EGFR inhibitor co-treatment and restores antitumor responses to these agents in vitro and in animal models. These data have potential clinical implications in that they unravel a metabolic vulnerability of drug-resistant lung CSCs, identify a novel SLC25A1 inhibitor and, lastly, provide the first line of evidence that drugs, which block SLC25A1 activity, when employed in combination with selected conventional antitumor agents, lead to a therapeutic benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41418-018-0101-z

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 139

Metadata

Authors
Fernandez, H. R., Gadre, S. M., Tan, M., Graham, G. T., Mosaoa, R., Ongkeko, M. S., Kim, K. A., Riggins, R. B., Parasido, E., Petrini, I., Pacini, S., Cheema, A., Varghese, R., Ressom, H. W., Zhang, Y., Albanese, C., Üren, A., Paige, M., Giaccone, G., & Avantaggiati, M. L.
Venue
Cell Death & Differentiation
Published
2018-04-12
Volume
25
Issue
7
Pages
1239-1258
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W2797928920
Cited by
139
References
9
FWCI
3.62
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41418-018-0101-z
The paper
Fernandez, H. R., Gadre, S. M., Tan, M., Graham, G. T., Mosaoa, R., Ongkeko, M. S., Kim, K. A., Riggins, R. B., Parasido, E., Petrini, I., Pacini, S., Cheema, A., Varghese, R., Ressom, H. W., Zhang, Y., Albanese, C., Üren, A., Paige, M., Giaccone, G., & Avantaggiati, M. L. (2018). The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death & Differentiation. https://doi.org/10.1038/s41418-018-0101-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.